11/1/2012

Sprint Bioscience and TPP Global Development agreed to collaborate in the development of small molecule choline kinase inhibitors for treatment of cancer. "Choline kinase is an exciting metabolic target and fits well within the rest of TPP's cancer metabolism portfolio," TPP CEO Tom Brown said.

Related Summaries